How Adaptogens Are Defined and Studied

The word "adaptogen" circulates widely in herbal and botanical supplement marketing, yet it originates in mid-twentieth-century Soviet pharmacology. The term was coined in 1947 by Nikolai Lazarev to describe substances that increase a biological organism's nonspecific resistance to stress. That narrow pharmacological definition — nonspecific, normalizing, and nontoxic — still anchors serious scientific discussion, even as commercial usage has stretched far beyond it.

This piece covers what that definition actually requires, how researchers attempt to test for adaptogenic activity, which plant compounds are most studied, and where the science encounters genuine friction. It does not address any particular product, dosage, or health outcome.

What the Formal Definition of "Adaptogen" Actually Requires

Lazarev's original criterion was expanded in the 1960s by Israeli Brekhman and I.V. Dardymov into three explicit conditions. First, an adaptogen must produce a nonspecific response — meaning it should increase resistance across multiple types of stressors (physical, chemical, biological) rather than targeting one pathway selectively. Second, it must have a normalizing influence: the effect should push a dysregulated physiological parameter toward a normal range regardless of the direction of dysregulation. Third, it must be innocuous — causing minimal disruption to normal physiological function at the doses under study.

These three criteria are demanding. Most pharmacological agents are highly specific: they bind a defined receptor and produce a defined directional effect. An adaptogen, by contrast, is supposed to modulate rather than drive. That distinction is important because it determines what kind of study design can actually test the claim. A standard dose-response experiment that looks for a single measurable endpoint may not capture normalizing or bidirectional effects.

Modern researchers have added a fourth operational criterion: the proposed mechanism should be traceable to molecular targets. The most studied candidates include the hypothalamic-pituitary-adrenal (HPA) axis, heat shock proteins, and the stress-activated protein kinase pathways. Without a plausible molecular mechanism, a substance cannot move from traditional use into evidence-based classification, regardless of how long it has appeared in ethnobotanical literature.

It is worth noting that "adaptogen" is not a regulatory category. The U.S. Food and Drug Administration classifies herbal products sold in the United States as dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which does not recognize "adaptogen" as a defined term. A manufacturer may use the word on a label as a structure-function descriptor only if the claim is truthful and not misleading, but no pre-market approval process verifies whether a product meets Lazarev's or Brekhman's criteria.

The Compounds, Organs, and Pathways Involved in Adaptogenic Research

Primary plant genera under study. The most extensively researched candidates include Panax ginseng (Asian ginseng), Eleutherococcus senticosus (Siberian ginseng, now formally reclassified and no longer in the Panax genus), Rhodiola rosea, Withania somnifera (ashwagandha), and Schisandra chinensis. Each contains a distinct class of putative active compounds: ginsenosides in Panax, eleutherosides in Eleutherococcus, rosavins and salidroside in Rhodiola, withanolides in Withania, and lignans in Schisandra.

The HPA axis. The hypothalamic-pituitary-adrenal axis is the primary hormonal cascade through which the body responds to perceived stress. It produces cortisol (in humans) via a chain beginning with corticotropin-releasing hormone (CRH) in the hypothalamus, proceeding to adrenocorticotropic hormone (ACTH) from the pituitary, and ending with cortisol secretion from the adrenal cortex. Several adaptogen candidates appear to modulate this axis, though the direction and magnitude of the effect depend on baseline cortisol levels, species studied, and extract preparation.

Heat shock proteins (HSPs). HSPs are molecular chaperones upregulated during cellular stress — heat, oxidative damage, or protein misfolding. Research on Rhodiola rosea extracts has examined whether salidroside and rosavin influence HSP70 expression. If confirmed, this would provide a plausible molecular mechanism for nonspecific stress resistance, though the clinical relevance of in vitro HSP findings remains an active area of investigation.

Nitric oxide (NO) signaling. Some studies have examined whether adaptogen extracts interact with nitric oxide synthase pathways, which are involved in vascular tone and cellular stress responses. This is a separate mechanism from HPA-axis modulation, illustrating that different plant genera may achieve superficially similar effects through distinct biochemical routes — a complication for any unified definition of "adaptogen."

The liver and phase I/II metabolism. Because adaptogen compounds are typically ingested as concentrated extracts, the liver's cytochrome P450 enzyme system processes them before systemic circulation. Certain compounds in this class have been identified as potential inhibitors or inducers of specific CYP isoforms, which has implications for how consistently extract effects are observed across individuals with different metabolic phenotypes.

Where Adaptogen Research Breaks Down or Produces Unexpected Results

The most persistent problem in adaptogen research is extract standardization. A Rhodiola rosea root extract standardized to 3% rosavins and 1% salidroside is not the same preparation as one standardized to 5% salidroside alone, yet both may appear in published studies under the same plant name. When results are pooled in meta-analyses, heterogeneous extracts are frequently treated as equivalent, which inflates the apparent evidence base and obscures genuine inconsistencies between trials.

The nonspecificity criterion creates a methodological paradox. Because an adaptogen is supposed to affect multiple systems simultaneously and in a normalizing (bidirectional) direction, standard randomized controlled trial designs — which test a single primary endpoint in a population selected to be homogeneous — may systematically underdetect the claimed effect. Conversely, measuring many endpoints simultaneously increases the probability of finding at least one statistically significant result by chance. Neither approach maps cleanly onto the theoretical definition.

Animal models dominate the early literature. Much of the foundational Soviet research used rodent swim-to-exhaustion or cold-stress models. Translating these findings to human physiology is not straightforward: rodents metabolize many plant compounds differently, stress physiology differs across species, and the doses used in animal studies are rarely scaled appropriately to human equivalents. Newer human trials have improved in design quality, but many remain small and industry-funded, which is a recognized source of bias in the broader dietary supplement literature.

Adulteration and misidentification add further noise. Botanical identity is not always confirmed at the extract level. Eleutherococcus senticosus has historically been sold under the name "Siberian ginseng," creating confusion with Panax species that have an entirely different active-compound profile. When researchers or consumers assume botanical equivalence based on a common name, the resulting data cannot be reliably interpreted. Just as third-party supplement testing can verify identity and purity at the product level, botanical identity verification at the raw-material stage requires separate authentication methods such as high-performance liquid chromatography (HPLC) or DNA barcoding.

The nontoxicity criterion is often assumed rather than demonstrated. Long traditional use is frequently cited as evidence of safety, but traditional preparations (decoctions, tinctures, whole-root powders) differ substantially in concentration from modern standardized extracts. Concentrated extracts can deliver active-compound loads that have no historical precedent, meaning safety data from traditional contexts does not transfer directly to commercial supplement formats.

What a Label or Certification Reveals About an Adaptogen Product — and What It Does Not

A supplement label bearing the name of an adaptogen plant is required under DSHEA to accurately identify the ingredient and not be misleading, but it is not required to demonstrate that the product meets Lazarev's three-part pharmacological definition. The label may state the plant genus and species (e.g., Withania somnifera), the plant part used (root, leaf, aerial parts), and the extract ratio or standardization level (e.g., "5% withanolides"). Each of these details carries meaningful information, but none is verified by the FDA before the product reaches sale.

Standardization percentages on labels describe the concentration of a marker compound in the extract, not necessarily the compound most responsible for the studied effects. Withanolides, for example, are a class of over 300 steroidal lactones; standardizing to total withanolides does not specify which individual withanolides are present or in what ratio. Two products with identical label claims may have substantially different phytochemical profiles.

Third-party certification seals — such as those from NSF International or USP — attest that the product contains what the label states and is free from specified contaminants. They do not evaluate whether the extract meets any definition of "adaptogen," whether the active compounds are bioavailable, or whether the preparation matches the formulation used in the clinical studies cited in marketing materials. The distinction between what a certification from NSF versus USP actually verifies is relevant here: both programs assess identity, potency, and purity within defined limits, but neither program has a testing protocol for "adaptogenic activity" as a category.

Structure-function claims on adaptogen labels — phrases such as "supports a healthy stress response" or "helps the body adapt to occasional stress" — are permitted under DSHEA provided they are accompanied by the required disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The presence of that disclaimer is legally required and signals the regulatory boundary between a structure-function claim and a disease claim, not a judgment about the underlying science.

The adaptogen concept began as a precise pharmacological hypothesis and has since become one of the most commercially diffuse terms in the herbal supplement category. The gap between the formal three-part definition and the heterogeneous body of research attempting to test it reflects a genuine challenge: the biology the term describes — nonspecific, normalizing, bidirectional — does not fit neatly into the experimental frameworks that generate the strongest clinical evidence. That tension is neither unique to adaptogens nor likely to resolve quickly.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.